Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of High-dose Hepatitis B Vaccine Among Drug Users
NCT02959775Phase 4Completed
- Sponsor
- Shanxi Medical University
- Start
- Aug 2014
- Primary completion
- May 2015
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
01
Overview
Phase 4, randomised, open-label trial of Hepatitis B vaccine in hepatitis B (HBV) (3 arms), sponsored by Shanxi Medical University. Primary endpoint: Number and Rate of Participants With Anti-HBs Seroconversion at 12 months. Started Aug 2014; status: completed.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT02959775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959775.